表紙
市場調査レポート

難治性白血病:パイプライン製品の分析

Refractory Leukemia - Pipeline Review, H1 2015

発行 Global Markets Direct 商品コード 305182
出版日 ページ情報 英文 41 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
難治性白血病:パイプライン製品の分析 Refractory Leukemia - Pipeline Review, H1 2015
出版日: 2015年06月17日 ページ情報: 英文 41 Pages
概要

白血病細胞のうち治療薬への耐性を示すものを難治性白血病と呼びます。主な徴候・症状として、皮膚の蒼白化や、歯茎が腫れあがる、軽度の感染症(肛門周辺のただれなど)、食欲不振、体重減少、骨・関節(膝関節・股関節・肩関節)の痛みや不快感などが挙げられます。疾病素質には年齢や、他の血液がん・障害の病歴、先天性障害、以前の化学療法・放射線治療の影響などがあります。治療オプションには、過去の治療で使用されなかった薬剤の使用や、骨髄移植に伴う条件付け療法などが含まれます。

当レポートでは、世界各国での難治性白血病治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

難治性白血病の概要

治療薬の開発

  • 難治性白血病向けパイプライン製品:概要
  • 難治性白血病向けパイプライン製品:比較分析

各企業で開発中の難治性白血病治療薬

パイプライン製品の概略

  • 治験段階の製品

難治性白血病治療薬:開発中の製品の一覧(企業別)

難治性白血病治療薬の開発に従事している企業

  • GlaxoSmithKline plc
  • 第一三共
  • Colby Pharmaceutical Company
  • Onconova Therapeutics, Inc.
  • Galileo Research s.r.l.

難治性白血病:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • トラメチニブ
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • リゴセルチブナトリウム
  • メシル酸エキサテカン
  • JVRS-100
  • TALL-104

難治性白血病治療薬:パイプライン製品の最新動向

難治性白血病治療薬:開発が休止状態の製品

難治性白血病治療薬:開発が中止された製品

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6797IDB

Summary

Global Markets Direct's, 'Refractory Leukemia - Pipeline Review, H1 2015', provides an overview of the Refractory Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Refractory Leukemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Refractory Leukemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Refractory Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Refractory Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Refractory Leukemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Refractory Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Refractory Leukemia Overview
  • Therapeutics Development
    • Pipeline Products for Refractory Leukemia - Overview
    • Pipeline Products for Refractory Leukemia - Comparative Analysis
  • Refractory Leukemia - Therapeutics under Development by Companies
  • Refractory Leukemia - Pipeline Products Glance
    • Clinical Stage Products
  • Refractory Leukemia - Products under Development by Companies
  • Refractory Leukemia - Companies Involved in Therapeutics Development
    • Bayer AG
    • Colby Pharmaceutical Company
    • Galileo Research s.r.l.
    • Novartis AG
    • XBiotech USA, Inc.
  • Refractory Leukemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BAY-1143572 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CA-18C3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JVRS-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TALL-104 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trametinib dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Refractory Leukemia - Recent Pipeline Updates
  • Refractory Leukemia - Dormant Projects
  • Refractory Leukemia - Dormant Projects
  • Refractory Leukemia - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Refractory Leukemia, H1 2015
  • Number of Products under Development for Refractory Leukemia - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Refractory Leukemia - Pipeline by Bayer AG, H1 2015
  • Refractory Leukemia - Pipeline by Colby Pharmaceutical Company, H1 2015
  • Refractory Leukemia - Pipeline by Galileo Research s.r.l., H1 2015
  • Refractory Leukemia - Pipeline by Novartis AG, H1 2015
  • Refractory Leukemia - Pipeline by XBiotech USA, Inc., H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Refractory Leukemia Therapeutics - Recent Pipeline Updates, H1 2015
  • Refractory Leukemia - Dormant Projects, H1 2015
  • Refractory Leukemia - Discontinued Products, H1 2015

List of Figures

  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top